Peptide antiestrogen compositions and methods for treating breast cancer
CA 2286877 A1 · Owner: The Regents Of The University Of California · Inventors: Pietras, Richard J.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Disclosed are methods and compositions comprising native site-specifically , mutagenized, and synthetic peptides comprising portions of the human estrogen receptor, or estrogen receptor co-activator and nucleic acid compositions , encoding these polypeptide compositions. Also disclosed are methods for synthesizing phosphotyrosyl and malonyltyrosyl peptide derivatives and their use as antiestrogen compositions in the treatment of breast cancers the , preparation of pharmaceutical compositions diagnostic kits, and the , development of related assays for use in antitumor therapies.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed April 14, 1998. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended April 14, 2018.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by April 14, 2020.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.